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Immunotherapy and immunosuppression 
in myeloid leukemia
Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are 
potentially life-threatening blood cancers characterized by the expansion of malignant 
myeloid cells in bone marrow and other organs. This thesis aimed at contributing to 
the understanding of the role of natural killer (NK) cells in AML and CMML with fo-
cus on the potential impact of the immunosuppression exerted by reactive oxygen spe-
cies (ROS) formed by the myeloid cell NOX2 enzyme. The thesis work has comprised 
in vitro studies of interactions between NK cells and primary myeloid leukemic cells 
along with analyses of NK cell repertoires in a clinical trial using a NOX2 inhibitor, 
histamine dihydrochloride (HDC) in conjunction with the NK cell-activating cyto-
kine interleukin-2 (IL-2) for the prevention of relapse of AML after the completion of 
chemotherapy. Paper I reports that the functions and viability of cytotoxic lympho-
cytes, including NK cells, were compromised by ROS produced by leukemic myeloid 
cells recovered from patients with CMML. The results are thus suggestive of a novel 
mechanism of leukemia-induced immunosuppression in this disease. Paper II analyzed 
aspects of myeloid cell populations in AML using blood samples from a clinical phase 
IV trial where AML patients (n=84) received HDC in conjunction with IL-2. The re-
sults imply that HDC may exert anti-leukemic efficacy by facilitating the maturation 
of myeloid cells, which impacts on the efficiency of immunotherapy with HDC/IL-2. 
In papers III and IV we explored the role of killer cell immunoglobulin-like receptors 
(KIR) for the relapse and survival of AML patients receiving HDC/IL-2. The results 
suggest that a subset of immature NK cells with low KIR expression may determine 
clinical outcome. In paper IV we further analyzed results from the above-referenced 
phase IV trial and observed that a past cytomegalovirus (CMV) infection predicted 
high relapse risk and poor survival, presumably by reducing the pool of immature NK 
cells. The results of paper V suggest that a dimorphism in the leader peptide of HLA-B 
is relevant to NK cell-mediated killing of AML cells and to the outcome of immuno-
therapy. In conclusion, this thesis work presents novel aspects of myeloid cell-induced 
immunosuppression in AML and CMML and identifies NK cell subsets of potential 
relevance to the benefit of immunotherapy with HDC/IL-2.
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